Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia

Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia

BackgroundPlasma biomarkers are preferable to invasive and expensive diagnostic tools, such as neuroimaging and lumbar puncture that are gold standard in the clinical management of Alzheimer’s Disease (AD). Here, we investigated plasma Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chai...

Full description

Bibliographic Details
Main Authors:	Assunta Ingannato, Silvia Bagnoli, Salvatore Mazzeo, Giulia Giacomucci, Valentina Bessi, Camilla Ferrari, Sandro Sorbi, Benedetta Nacmias
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Endocrinology
Subjects:	Alzheimer's disease preclinical stages plasma biomarkers glial fibrillary acidic protein neurofilament light chain phosphorylated-tau-181
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1375302/full

Similar Items

Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients
by: Assunta Ingannato, et al.
Published: (2021-09-01)

The Effect of CAG Repeats within the Non-Pathological Range in the HTT Gene on Cognitive Functions in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment
by: Valentina Bessi, et al.
Published: (2021-06-01)

CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study
by: Valentina Moschini, et al.
Published: (2022-03-01)

Serum GFAP, NfL, and tau concentrations are associated with worse neurobehavioral functioning following mild, moderate, and severe TBI: a cross-sectional multiple-cohort study
by: Katie A. Edwards, et al.
Published: (2024-01-01)

Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
by: Johannes Heinrich Alexander Piel, et al.
Published: (2024-03-01)

Dual Effect of <i>PER2</i> C111G Polymorphism on Cognitive Functions across Progression from Subjective Cognitive Decline to Mild Cognitive Impairment
by: Salvatore Mazzeo, et al.
Published: (2021-04-01)

Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury
by: Katerina Vlasakova, et al.
Published: (2024-01-01)

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
by: Giulia Giacomucci, et al.
Published: (2021-01-01)

The Huntington’s Disease Gene in an Italian Cohort of Patients with Bipolar Disorder
by: Camilla Ferrari, et al.
Published: (2023-08-01)

Influence of <i>ApoE</i> Genotype and <i>Clock</i> T3111C Interaction with Cardiovascular Risk Factors on the Progression to Alzheimer’s Disease in Subjective Cognitive Decline and Mild Cognitive Impairment Patients
by: Valentina Bessi, et al.
Published: (2020-05-01)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study
by: Marta Simone, et al.
Published: (2023-02-01)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
by: Christopher Clark, et al.
Published: (2021-03-01)

Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies
by: Xuechun Chang, et al.
Published: (2021-03-01)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
by: Nuole Zhu, et al.
Published: (2021-12-01)

Differences and Similarities in Empathy Deficit and Its Neural Basis between Logopenic and Amnesic Alzheimer’s Disease
by: Giulia Giacomucci, et al.
Published: (2023-01-01)

Beneficial Effect of Phenytoin and Carbamazepine on GFAP Gene Expression and Mutant GFAP Folding in a Cellular Model of Alexander’s Disease
by: Tiziana Bachetti, et al.
Published: (2021-12-01)

GFAP-Negative Subcutaneous Sacrococcygeal Extraspinal Ependymoma
by: Kazuya Goto, et al.
Published: (2021-06-01)

A case of glial fibrillary acidotic protein (GFAP) meningoencephalitis with rheumatoid arthritis
by: Mehri Salari, et al.
Published: (2023-03-01)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
by: Wei Qin, et al.
Published: (2022-06-01)

Case report: Headache as the sole neurological symptom in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
by: Eslam Shosha, et al.
Published: (2024-04-01)

Uncommon manifestations of a rare disease: a case of autoimmune GFAP astrocytopathy
by: Hong Di, et al.
Published: (2021-01-01)

Systematic assessment of plasma biomarkers in spinocerebellar ataxia
by: Xue-Ning Shen, et al.
Published: (2023-06-01)

Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
by: Shugang Cao, et al.
Published: (2023-05-01)

Alzheimer’s Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus
by: Salvatore Mazzeo, et al.
Published: (2022-06-01)

Degradation of EEG microstates patterns in subjective cognitive decline and mild cognitive impairment: Early biomarkers along the Alzheimer’s Disease continuum?
by: Michael Lassi, et al.
Published: (2023-01-01)

Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy
by: Akio Kimura, et al.
Published: (2022-03-01)

Soluble curcumin prevents cadmium cytotoxicity in primary rat astrocytes by improving a lack of GFAP and glucose-6-phosphate-dehydrogenase
by: V. S. Nedzvetsky, et al.
Published: (2018-11-01)

Relapsing Autoimmune GFAP Astrocytopathy: Case Report
by: Ekaterina O. Chekanova, et al.
Published: (2023-12-01)

Whether Serum Glial Fibrillary Acidic Protein (GFAP) Can Be Used as a Diagnostic Biomarker in Patients With Glioblastoma?
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01)

Emerging biomarkers for improving pregnancy planning in multiple sclerosis
by: Juan Pablo Cuello, et al.
Published: (2024-02-01)

Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases
by: Su-Hyun Kim, et al.
Published: (2021-05-01)

Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL
by: Chih-Hao Chen, et al.
Published: (2020-04-01)

Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease
by: Alessandro Dinoto, et al.
Published: (2022-03-01)

Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease
by: Huajing You, et al.
Published: (2021-11-01)

Retinal and Optic Nerve Integrity Following Monocular Inactivation for the Treatment of Amblyopia
by: Nadia R. DiCostanzo, et al.
Published: (2020-06-01)

Distribution of GFAP in Squamata: Extended Immunonegative Areas, Astrocytes, High Diversity, and Their Bearing on Evolution
by: Dávid Lõrincz, et al.
Published: (2020-08-01)

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: To Identify Its Diagnosis, Management and Prognosis (GFAP-AID) Registry: Study Protocol for an Ambispective, Multicenter Registry in China
by: Yang J, et al.
Published: (2022-06-01)

The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study
by: Jie Wu, et al.
Published: (2024-02-01)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
by: Kelsey R. Thomas, et al.
Published: (2021-01-01)

Area postrema syndrome with linear enhancement along the surface of the brainstem and fourth ventricle in autoimmune GFAP astrocytopathy
by: Xinming Liang, et al.
Published: (2023-02-01)